M45.01 Axial spondyloarthrititis M45.01
Conditions
Interventions
Group 1: Biologics-naive patients undergo a baseline examination. This is followed by a control of the same arm after 3-6 months. No control arm available.
Sponsors
Rheumazentrum Ruhrgebiet
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis of spondyloarthritis (radiographic or nonradiographic axial spondyloarthritis, or psoriatic arthritis with axial skeletal involvement). Clinical indication for [18F]fluoride PET examination. Clinical indication for initiation of drug therapy (TNF blocker, interleuking-17 blocker, Janus kinase inhibitor, NSAID.) for a period of at least one month.
Exclusion criteria
Exclusion criteria: -Pregnancy -Severe renal insufficiency -Cardiac pacemaker -Non-MR compatible foreign material -Severe claustrophobia -Known allergy to contrast media -Inability to understand the patient information sheet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the anti-inflammatory and anti-osteoblastic effects of various drug therapies (TNF blocker, interleukin-17 blocker Janus kinase inhibitor, NSAID) in patients with active spondyloarthritis during the course. To investigate the correlation of clinical disease activity with the extent and course of inflammatory changes (MRI) or increased metabolic ([18F]fluoride PET) activity. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the examination results of native MRI examinations in the regions of the ankle, spine and sacroiliac joints of spondyloarthritis patients before and after drug therapy, among others, with the examination results obtained by means of [18F]fluoride PET/MRI. In detail, the skeletal sites showing inflammatory activity in MRI are compared to the exact anatomical regions showing metabolic activity in [18F]fluoride PET/MRI. | — |
Countries
Germany
Contacts
Public ContactStyliani Tsiami
Rheumazentrum Ruhrgebiet
Outcome results
None listed